Destination XL Group, Inc. (DXLG)
NASDAQ: DXLG · Real-Time Price · USD
1.280
+0.010 (0.79%)
Aug 13, 2025, 9:42 AM - Market open
Revance Therapeutics Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Revance Therapeutics stock has a target of 2.50, which predicts a 95.31% increase from the current stock price of 1.28.
Price Target: $2.50 (+95.31%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 21, 2025.
Analyst Ratings
According to 1 stock analyst, the rating for Revance Therapeutics is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| DA Davidson | DA Davidson | Strong Buy Maintains $3 → $2.5 | Strong Buy | Maintains | $3 → $2.5 | +95.31% | Mar 21, 2025 |
| DA Davidson | DA Davidson | Strong Buy Maintains $3.5 → $3 | Strong Buy | Maintains | $3.5 → $3 | +134.38% | Dec 24, 2024 |
| DA Davidson | DA Davidson | Strong Buy Maintains $6 → $4 | Strong Buy | Maintains | $6 → $4 | +212.50% | Aug 30, 2024 |
| Craig-Hallum | Craig-Hallum | Hold Maintains $3.5 → $3 | Hold | Maintains | $3.5 → $3 | +134.38% | May 31, 2024 |
| Craig-Hallum | Craig-Hallum | Strong Buy → Hold Downgrades n/a | Strong Buy → Hold | Downgrades | n/a | n/a | Nov 20, 2023 |
Financial Forecast
Revenue This Year
457.90M
from 467.02M
Decreased by -1.95%
Revenue Next Year
474.20M
from 457.90M
Increased by 3.56%
EPS This Year
-0.14
from 0.05
EPS Next Year
-0.05
from -0.14
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 473.4M | 494.6M | 525.0M | ||
| Avg | 457.9M | 474.2M | 510.0M | ||
| Low | 438.1M | 449.6M | 490.0M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 1.4% | 8.0% | 10.7% | ||
| Avg | -2.0% | 3.6% | 7.5% | ||
| Low | -6.2% | -1.8% | 3.3% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -0.12 | 0.03 | 0.07 | ||
| Avg | -0.14 | -0.05 | 0.07 | ||
| Low | -0.17 | -0.13 | 0.07 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.